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In this study, we demonstrated that tissue inhibitor of metalloproteinases (TIMP) produced by human bone marrow stromal cell line KM-102 
had erythroid-potentiating activity (EPA) which stimulates the proliferation of erythroid progenitor cells. We, then, propose a scheme for the bifunc- 
tional role of TIMP/EPA in hematopoietic microenvironment, that is, the maintenance of the integrity of bone marrow matrix and the proliferation 
of erythroid progenitor cells proceeding on the matrix. 
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1. INTRODUCTION 
Recently, Docherty et al. [l] reported the amino acid 
sequence of human TIMP predicted from its com- 
plementary DNA, and found that it is identical to a 
28 kDa protein referred to as EPA and produced by the 
human T-lymphoblast cell line MO [6]. This EPA 
stimulates colony formation by early and late 
erythroid-committed stem cells (BFU-E and CFU-E, 
respectively) from human bone marrow [3] and by the 
K562 human erythroleukemia cell line [4]. On the other 
hand, studies utilizing the long-term bone marrow 
cultures indicated that adherent stromal cells 
(fibroblastoid cells, adipocytes, endothelial cells, and 
macrophages) play a significant role in bone marrow 
hematopoiesis [5,6]. In this culture system, 
fibroblastoid stromal cells are a major population of 
the adherent layer and most of them are suggested to be 
derived from adventitial reticular cells situated in 
hematopoietic cords of the bone marrow [7]. Primary 
adherent cells or established fibroblastoid cell lines 
from human bone marrow stroma demonstrated a 
burst-promoting activity (BPA) that stimulates the 
growth of BFU-E [8-121. BPA resides in granulocyte- 
macrophage colony-stimulating factor [13-151, 
interleukin-3 [16] and EPA [3]. Thus, a question arose 
as to whether or not TIMP derived from bone marrow 
stroma has EPA activity. Here, we describe the 
purification of TIMP from the supernatant of serum- 
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free cultures of the human bone marrow fibroblastoid 
stromal cell line KM-102 and the presence of EPA in 
the purified material. 
2. MATERIALS AND METHODS 
2.1. Culture of human bone marrow stromal cell lines 
The human bone marrow stromal cell lines were maintained as 
described previously [8]. For preparation of serum-free conditioned 
medium, cell cultures were maintained for 7 days after a confluent 
layer had developed. Then the cells were washed 3 times in Dulbec- 
co’s modified phosphate-buffered saline (Sigma) and placed in 
serum-free Iscove’s medium (Boehringer-Mannheim) containing 
phorbol myristate acetate (PMA) (10 ng/ml; Sigma) and calcium 
ionophore A23187 (0.2yM; Sigma) for an additional 48 h. After 
harvesting of the conditioned medium, cells were re-fed with 5% fetal 
bovine serum (Hy-Clone)-Iscove’s medium and incubated for 2 days, 
and then serum-free medium was again employed and collected again 
as in the aforementioned way. Pooled KM-102 culture medium was 
centrifuged (3000 rpm, 30 min), filtered (0.45hrn filter), and stored 
at - 20°C until used. 
2.2. Assay for EPA 
EPA assay was performed with human peripheral blood cells ob- 
tained from a normal donor as described previously [8] except for 
several modifications as follows: nonadherent bone marrow cells 
(2.5 x lti10.5 ml/well) were cultured in 24-well tissue culture plates; 
each well contained 500 ~1 of methylcellulose (Dow Chemicals) mix- 
ture. Cultures were incubated for 8 days; then 0.75 U/ml of 
erythropoietin was added to each well. Erythroid bursts were scored 
at 16 days. 
2.3. Purification of TIMP 
TIMP was purified in a homogeneous form KM-102 cell- 
conditioned medium by use of a monoclonal-antibody affinity col- 
umn [17]. TIMP concentration was measured by a sandwich enzyme 
immunoassay [181. 
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2.4. Assay of collagenase and TIMP activities 
The activities of collagenase and TIMP were determined by the 
method of Terato et al. [19] using [‘4C]glycine-labelled collagen. 1 U 
of collagenase activity is the amount of protein necessary to degrade 
1 pg collagen/min at pH 7.5 and 35°C. 1 U of TIMP activity is defin- 
ed as the amount of protein required for 50% inhibition of 2 U of 
collagenase. 
2.5. Sodium dodecyi sulfate-polyacrylamide gel electrophoresis 
and immunoblotting 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS- 
PAGE) was carried out by the method of Laemmli [20]. Molecular 
weight markers (Bio-Rad) were used as standards. After elec- 
trophoresis, the protein in the gel was transferred onto a 
nitrocellulose sheet. The sheet was then soaked in 4pg/ml Fab’ 
(clone 7-6Cl)-peroxidase conjugate. Staining was performed by the 
hydrogen peroxide system with 3,3’-diaminobenzidine. 
3. RESULTS AND DISCUSSION 
Collagenase activities and TIMP concentrations in 
media from both unstimulated and stimulated serum- 
free cultures of 5 human stromal cell lines were deter- 
mined and are summarized in Table I. Stimulation by 
PMA and a calcium ionophore induced 2-15 times 
more production of collagenase in these cell lines with 
the exception of KM-105. The production of TIMP 
was, however, stimulated only rather slightly (1 .l-1.7 
times) in any of these cell lines. KM-102 cell- 
conditioned medium seemed to be the richest in TIMP 
among the conditioned media of the 5 cell lines. Col- 
lagenase was secreted essentially as a proenzyme that 
was activated after APMA treatment. 
Highly purified TIMP was subjected to SDS-PAGE. 
The protein migrated as a single band visualized by 
either Coomassie brilliant blue or immunostaining and 
its mobility indicated a molecular weight of 27 kDa 
(Fig. la). Purified TIMP blocked the collagenase ac- 
tivity from the KM-102 stromal cell line together with 
the collagenases from chick skin [21], bovine dental 
pulp [22], and dog 1231 and human [24] polymor- 
phonuclear leukocytes, but not bacterial collagenase 
(data not shown). The blockage of KM-102 collagenase 
activity was confirmed by the detection of diminished 
degradation products (aA and a’) of collagen in the 
presence of TIMP (Fig. lb). 
Table I 
Production of collagenase and TIMP by clonal human bone marrow 
stromal cell lines 
Cell line Unstimulated PMA and Ca ionophore 
Collagenase TIMP Collagenase TIMP 
(mU/ml) (ug/ml) (mu/ml) (/rg/ml) 
KM-101 20.1(O) 0.41 285.9(1.3) 0.69 
KM-102 4.3(O) 1.23 22.1(O) 1.73 
KM-103 16.5(O) 0.38 46.0(O) 0.47 
KM-104 6.1(O) 0.42 13.3(O) 0.48 
KM-105 10.1(O) 0.23 8.5(O) 0.32 
Enzyme activities without APMA activation are given in parentheses 
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Fig. 1. Homogeneity and inhibitory activity of KM-102 cell TIMP. 
(a) SDS-12% PAGE of purified TIMP immunoblotted (1) or stained 
with Coomassie brilliant blue (2), or of standard proteins (3). (b) 
SDSd% PAGE fluorography. [%]Glycine-labelled collagen (53 pg) 
was incubated alone (I), with 21 mU collagenase partially purified 
from KM-102 cell-conditioned medium (2), or with 13 ng (159 mu) 
KM-102 cell TIMP (3) at 21°C for 96 h. X-ray film was exposed to 
the gel for 4 days at -70°C. 
As shown in Table II, we demonstrated that the 
purified TIMP has EPA activity. That is, the number 
of colonies derived from erythroid stem cells increased 
by the supplementation with 6.25 ng/ml or more 
purified TIMP. Furthermore, the addition of anti- 
TIMP monoclonal antibody [17] neutralized the EPA 
activity of KM-102 cell-derived TIMP, as evidenced by 
the significant decrease in the number of BFU-E- or 
CFU-E-derived colonies compared with the number in 
the control cultures. This reduction was also observed 
in the control cultures when the antibody was added 
(data not shown), thus suggesting the presence of 
TIMP/EPA in the commercially obtained fetal calf 
serum used and its neutralization by the added an- 
tibody. 
Generally, most connective tissue cells secrete at least 
3 distinct matrix metalloproteinases, interstitial col- 
Table II 
Number of BFU-E and CFU-E colonies in methylcellulose cultures 
containing different doses of KM-102 TIMP 
0 ng/ml 6.25 ng/ml 25 ng/ml 100 ng/ml 
BFU-E colony number (mean + SD, n = 4) 
16.7 + 1.5 31.5 f 5.0* 23.0 + 2.0 
(9.5 * 3.5) 
23.5 f 2.0 
0 ma/ml 6.25 &ml 12.5 ng/ml 25 ng/ml 50 ng/ml 
36.3 * 8.3 47.3 + 4.9 52.8 + 5.5 65.8 k 5.4* 38.5 + 8.2 
(14.3 + 3.4) 
Numbers in parentheses are mean colony numbers formed in the 
presence of anti-TIMP monoclonal antibody (clone 7-6C1, 
880ag/ml; 1: 10 dilution for BFU-E, 1: 50 dilution for CFU-E). 
* Significant difference (P < 0.01) from the corresponding control 
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Fig. 2. Proposed scheme for bifunctional role of TIMPIEPA in hematopoietic microenvironment. MMP, matrix metalloproteinases. 
lagenase, gelatinase (type IV collagenase) and 
stromelysin, which could mutually be responsible for 
the turnover of most protein components of ex- 
tracellular matrix, that is, collagens I-V, VII, and X, 
gelatin, elastin, proteoglycan core protein, fibronectin, 
and laminin [25-361. On the other hand, these connec- 
tive tissue cells also produce a specific inhibitor of these 
matrix metalloproteinases called TIMP [37-421. As a 
consequence, the balance between the activities of 
matrix metalloproteinases and TIMP is thought to be 
of central importance for the maintenance of connec- 
tive tissue integrity. Essentially the same situation may 
apply in the bone marrow matrix (Fig. 2). 
In conclusion, bone marrow stromal cells were 
demonstrated to produce a bifunctional protein that 
not only acts as a metalloproteinase inhibitor (TIMP) 
but also has EPA activity to stimulate the proliferation 
of erythroid progenitor cells. 
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